-
[show abstract]
[hide abstract]
ABSTRACT: Numerous epidemiologic studies have demonstrated that premenstrual disorders (PMDs) begin during the teenage years. At least 20 % of adolescents experience moderate-to-severe premenstrual symptoms associated with functional impairment. Premenstrual syndrome (PMS) consists of physical and/or psychological premenstrual symptoms that interfere with functioning. Symptoms are triggered by ovulation and resolve within the first few days of menses. The prevalence of premenstrual dysphoric disorder (PMDD), a severe form of PMS accompanied by affective symptoms, is likely equal to or higher than in adults. The diagnosis of a PMD requires a medical and psychological history and physical examination but it is the daily prospective charting of bothersome symptoms for two menstrual cycles that will clearly determine if the symptoms are related to a PMD or to another underlying medical or psychiatric diagnosis. The number and type of symptoms are less important than the timing. Randomized controlled trials of pharmacologic treatments in teens with moderate-to-severe PMS and PMDD have yet to be performed. However, clinical experience suggests that treatments that are effective for adults can be used in adolescents. PMS can be ameliorated by education about the nature of the disorder, improving calcium intake, performing exercise and reducing stress, but to treat severe PMS or PMDD pharmacologic therapy is usually required. Eliminating ovulation with certain hormonal contraceptive formulations or gonadotropin-releasing hormone agonists will be discussed. Serotonergic agonists are a first-line therapy for adults, and some serotonin reuptake inhibitors such as fluoxetine and escitalopram can be administered safely to teens.
Paediatric Drugs 03/2013; · 1.79 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To review the current knowledge about the prevalence, diagnosis, and management of premenstrual syndromes in adolescents.
Large epidemiologic studies addressing adolescent premenstrual disorders, clinical presentation, and comorbidity with other disorders have yet to be performed. Randomized controlled treatment trials for teens with moderate-to-severe premenstrual syndrome or the more severe affective predominant, premenstrual dysphoric disorder still are sorely lacking. This review will present an updated review of the published studies with respect to premenstrual syndrome and premenstrual dysphoric disorder in adolescents in the context of the large body of literature regarding presentation, diagnosis, and treatment in adult women.
Premenstrual disorders likely start in the teen years. At least 20% of adolescents may experience moderate-to-severe premenstrual symptoms associated with functional impairment. Current treatment includes lifestyle recommendations and pharmacologic agents that suppress the rise and fall of ovarian steroids or augment serotonin.
Current opinion in obstetrics & gynecology 11/2008; 20(5):455-63. · 2.49 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: It is estimated that 60-80% of menstruating women experience some degree of premenstrual symptomatology; however the diagnosis of premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD) is assigned, using defined criteria, to those women whose lives are significantly affected by moderate to severe symptoms. Though these diagnoses are not frequently made in the adolescent group, the literature suggests that a similar proportion of teens would also meet criteria for PMS/PMDD. In adolescents, treatment should begin with education and lifestyle changes; however, many of the treatments used commonly in adults can also be employed safely in severe adolescent cases.
Pediatric endocrinology reviews: PER 02/2006; 3 Suppl 1:132-7.
-
[show abstract]
[hide abstract]
ABSTRACT: Various mood and anxiety disorders are more prevalent in reproductive-aged women, and appear to be linked to hormonal and reproductive events. Premenstrual affective disorders consist of premenstrual syndrome, premenstrual dysphoric disorder, and premenstrual exacerbation of mood or anxiety disorders. Postpartum affective disorders can range from postpartum "blues" to postpartum depression with or without psychosis, and also include anxiety disorders, such as panic disorder, generalized anxiety disorder, social phobia, and obsessive-compulsive disorder. In perimenopausal women, the vulnerability to mood and anxiety disorders is increased. All of these disorders share risk factors, and have etiologic features in common, such as exposure to the rise and fall of ovarian sex steroids. The following is a review of these syndromes and their etiology, diagnosis, and treatment.
Current Psychiatry Reports 01/2003; 4(6):419-28. · 2.71 Impact Factor
